Published in Acta Pharmacol Sin on June 09, 2014
Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes. PLoS One (2016) 1.40
Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol (2015) 0.84
Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture. Cent European J Urol (2015) 0.83
Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Front Pharmacol (2015) 0.82
SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget (2016) 0.78
Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) (2017) 0.77
Polyglutamine androgen receptor-mediated neuromuscular disease. Cell Mol Life Sci (2016) 0.77
Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting. Asian J Androl (2016) 0.77
The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. Stem Cells Int (2016) 0.76
Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev (2016) 0.76
Ligand fishing using new chitosan based functionalized Androgen Receptor magnetic particles. J Pharm Biomed Anal (2016) 0.75
NMR WaterLOGSY Reveals Weak Binding of Bisphenol A with Amyloid Fibers of a Conserved 11 Residue Peptide from Androgen Receptor. PLoS One (2016) 0.75
The androgen-induced protein AIbZIP facilitates proliferation of prostate cancer cells through downregulation of p21 expression. Sci Rep (2016) 0.75
Phytosteroids beyond estrogens: Regulators of reproductive and endocrine function in natural products. Mol Cell Endocrinol (2016) 0.75
Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget (2017) 0.75
Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions. Mol Biosyst (2016) 0.75
Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene (2016) 0.75
AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers (Basel) (2017) 0.75
Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther (2016) 0.75
Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. Oncotarget (2017) 0.75
Family reunion of nuclear hormone receptors: structures, diseases, and drug discovery. Acta Pharmacol Sin (2015) 0.75
Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer. Sci Rep (2017) 0.75
Ca(2+)/Calmodulin-Dependent Protein Kinase II and Androgen Signaling Pathways Modulate MEF2 Activity in Testosterone-Induced Cardiac Myocyte Hypertrophy. Front Pharmacol (2017) 0.75
Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status. Mol Cell Biochem (2017) 0.75
An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLoS One (2017) 0.75
Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase. Int J Mol Med (2017) 0.75
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. Curr Genomics (2017) 0.75
Binding of bisphenol A, bisphenol AF, and bisphenol S on the androgen receptor: Coregulator recruitment and stimulation of potential interaction sites. Toxicol In Vitro (2017) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 16.57
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The development of androgen-independent prostate cancer. Nat Rev Cancer (2001) 11.88
A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature (1997) 11.15
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (1991) 9.89
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
Androgen receptor in prostate cancer. Endocr Rev (2004) 7.92
Steroid hormone receptors: many actors in search of a plot. Cell (1995) 7.22
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
High-resolution protein structure determination by serial femtosecond crystallography. Science (2012) 6.90
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell (2005) 5.38
Molecular biology of the androgen receptor. J Clin Oncol (2002) 5.08
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature (1995) 4.79
A structural role for hormone in the thyroid hormone receptor. Nature (1995) 4.27
A unified nomenclature system for the nuclear receptor superfamily. Cell (1999) 4.23
Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev (1995) 4.22
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature (2013) 3.77
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem (1968) 3.54
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature (2008) 3.44
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science (1988) 3.40
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer (2009) 3.33
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell (2006) 3.12
Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature (2002) 3.11
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 2.81
Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem (1991) 2.79
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem (2000) 2.60
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem (2000) 2.58
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A (2001) 2.44
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci U S A (1988) 2.39
Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell (2004) 2.38
A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem (1994) 2.35
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res (2003) 2.07
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc Natl Acad Sci U S A (2007) 2.04
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem (1999) 2.00
A surface on the androgen receptor that allosterically regulates coactivator binding. Proc Natl Acad Sci U S A (2007) 1.97
Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A (2004) 1.97
Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (2001) 1.93
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol (2004) 1.91
The androgen receptor gene mutations database: 2012 update. Hum Mutat (2012) 1.84
Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol (1995) 1.83
Androgen insensitivity syndrome. Lancet (2012) 1.82
Molecular regulation of androgen action in prostate cancer. J Cell Biochem (2006) 1.81
Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci (2000) 1.77
Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet (1989) 1.74
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
Androgen receptors in prostate cancer. Endocr Relat Cancer (2002) 1.71
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res (2012) 1.71
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
Metabolism of testosterone and action of metabolites on prostate glands grown in organ culture. Nature (1968) 1.71
The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem (2004) 1.66
Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology (1990) 1.64
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem (2003) 1.61
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Molecular basis of androgen insensitivity. Mol Cell Endocrinol (2001) 1.60
Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem (2000) 1.59
Activation of nuclear receptors: a perspective from structural genomics. Structure (2003) 1.59
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem (2002) 1.57
Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res (2006) 1.56
Abscisic acid perception and signaling: structural mechanisms and applications. Acta Pharmacol Sin (2014) 0.83
Molecular assembly of rhodopsin with G protein-coupled receptor kinases. Cell Res (2017) 0.75
Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors. Cell (2017) 0.75